Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1967 1
1972 2
1973 2
1974 2
1975 2
1976 2
1977 2
1978 2
1979 2
1980 2
1981 2
1982 1
1983 5
1984 4
1985 2
1986 1
1987 5
1988 8
1989 3
1990 5
1991 5
1992 5
1993 5
1994 6
1995 6
1996 6
1997 12
1998 10
1999 15
2000 10
2001 16
2002 22
2003 17
2004 11
2005 6
2006 19
2007 10
2008 15
2009 24
2010 21
2011 28
2012 26
2013 30
2014 34
2015 28
2016 24
2017 35
2018 27
2019 27
2020 49
2021 43
2022 38
2023 45
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

664 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators. Kelley RK, et al. Among authors: chan sl. Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16. Lancet. 2023. PMID: 37075781 Clinical Trial.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Among authors: chan sl. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma.
Xiong Z, Chan SL, Zhou J, Vong JSL, Kwong TT, Zeng X, Wu H, Cao J, Tu Y, Feng Y, Yang W, Wong PP, Si-Tou WW, Liu X, Wang J, Tang W, Liang Z, Lu J, Li KM, Low JT, Chan MW, Leung HHW, Chan AWH, To KF, Yip KY, Lo YMD, Sung JJ, Cheng AS. Xiong Z, et al. Among authors: chan sl. Gut. 2023 Sep;72(9):1758-1773. doi: 10.1136/gutjnl-2022-328364. Epub 2023 Apr 5. Gut. 2023. PMID: 37019619 Free PMC article.
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK. Abou-Alfa GK, et al. Among authors: chan sl. N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002. N Engl J Med. 2018. PMID: 29972759 Free PMC article. Clinical Trial.
Epigenetic analysis of cell-free DNA by fragmentomic profiling.
Zhou Q, Kang G, Jiang P, Qiao R, Lam WKJ, Yu SCY, Ma ML, Ji L, Cheng SH, Gai W, Peng W, Shang H, Chan RWY, Chan SL, Wong GLH, Hiraki LT, Volpi S, Wong VWS, Wong J, Chiu RWK, Chan KCA, Lo YMD. Zhou Q, et al. Among authors: chan sl. Proc Natl Acad Sci U S A. 2022 Nov;119(44):e2209852119. doi: 10.1073/pnas.2209852119. Epub 2022 Oct 26. Proc Natl Acad Sci U S A. 2022. PMID: 36288287 Free PMC article.
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region.
Kim DY, Toan BN, Tan CK, Hasan I, Setiawan L, Yu ML, Izumi N, Huyen NN, Chow PK, Mohamed R, Chan SL, Tanwandee T, Lee TY, Hai TTN, Yang T, Lee WC, Chan HLY. Kim DY, et al. Among authors: chan sl. Clin Mol Hepatol. 2023 Apr;29(2):277-292. doi: 10.3350/cmh.2022.0212. Epub 2023 Jan 30. Clin Mol Hepatol. 2023. PMID: 36710606 Free PMC article. Review.
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).
Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Dao TV, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgué A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle PR, Ali S, Gupta C, Makowsky M, Kurland JF, Negro A, Sangro B. Abou-Alfa GK, et al. Among authors: chan sl. Future Oncol. 2023 Dec;19(38):2505-2516. doi: 10.2217/fon-2023-0486. Epub 2023 Sep 6. Future Oncol. 2023. PMID: 37671641 Free article. Review.
664 results